Cancer immunotherapy: The interferon-α experience

Seminars in Oncology

Volumn 29, Issue 3 SUPPL. 7, 2002, Pages 18-26

  Kirkwood, John ^a  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ALPHA2B INTERFERON; ANTINEOPLASTIC AGENT; CAPECITABINE; CISPLATIN; CYTARABINE; DACARBAZINE; FLUOROURACIL; INTERLEUKIN 2; MEGESTROL ACETATE; RETINOIC ACID; VINBLASTINE; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANOREXIA; ANTINEOPLASTIC ACTIVITY; BLOOD DISEASE; CANCER IMMUNOTHERAPY; CHRONIC MYELOID LEUKEMIA; COGNITIVE DEFECT; COLORECTAL CARCINOMA; CONDYLOMA ACUMINATUM; DEPRESSION; FATIGUE; FLU LIKE SYNDROME; FOOD AND DRUG ADMINISTRATION; HAIRY CELL LEUKEMIA; HEPATITIS C; HUMAN; KAPOSI SARCOMA; KIDNEY CARCINOMA; MELANOMA; MULTIPLE MYELOMA; PRIORITY JOURNAL; REVIEW; SEXUAL DYSFUNCTION; SOLID TUMOR; WEIGHT REDUCTION;

EID: 0036269757     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/sonc.2002.33078     Document Type: Article

References (74)

1. The human interferon-α species and hybrid proteins
2. Biological properties of recombinant α-interferons: 40th Anniversary of the discovery of interferons
3. Pharmacology of cancer biotherapeutics: Interferons
4. IFNα-2 therapy of hairy cell leukemia: A multicenter study of 64 patients
5. Gallium scans in patients with mediastinal Hodgkin's disease treated with chemotherapy
6. A comparison of polychemotherapy and melphalan/prednisone for primary remission induction, and interferon-alpha for maintenance treatment, in multiple myeloma. A prospective trial of the German Myeloma Treatment Group
7. A randomized trial of maintenance versus no maintenance melphalan and prednisone in responding multiple myeloma patients
8. Role of interferon in multiple myeloma
9. Maintenance therapy for remission in myeloma with Intron A following high-dose melphalan and either an autologous bone marrow transplantation or peripheral stem cell rescue
10. Systemic adjuvant treatment of high-risk melanoma: The role of interferon alfa- 2B and other immunotherapies
11. Interferon-alpha in tumor immunity and immunotherapy
12. Interferon alfa-2B adjuvant therapy of high risk resected cutaneous melanoma: The Eastern Cooperative Oncology Group trial EST 1684
13. High-dose interferon alfa-2b significantly prolonged relapse-free and overall survival compared with the GM-2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: Results of inter-group trial E1694/S9512/C 509801
14. High-and low-dose interferon alfa-2b in high-risk melanoma: First analysis of intergroup trial E1690/S9111/C 9190
15. The emerging role of cytokines in the treatment of advanced melanoma
16. Phase III randomized trial of cisplatin, vinblastine and dacarbazine (CVD) plus interleukin-2 (IL2) and interferon-alpha-2b (INF) versus CVD in patients with metastatic melanoma
17. Regimens with or without interferon-alpha as treatment for metastatic melanoma and renal cell carcinoma: An overview of randomized trials
18. Viewpoint on the impact of interferon in the treatment of multiple myeloma: Benefit for a small proportion of patients?
19. A randomized trial comparing interferon-alpha with busulfan for newly diagnosed chronic myelogenous leukemia in chronic phase
20. Chronic myelogenous leukemia: A concise update
21. Biotherapy of chronic meyelogenous leukemia with IFN
22. Randomized comparison of interferon-alpha with busulfan and hydroxyurea in chronic myelogenous leukemia
23. Interferon-α 2A as compared chemotherapy for the treatment of chronic myeloid leukemia
24. Interferon a-2B combined with cytarabine versus interferon alone in chronic myelogenous leukemia
25. UK Medical Research Council randomised, multicentre trial of interferon-alpha n1 for chronic myeloid leukaemia: Improved survival irrespective of cytogenetic response. The UK Medical Research Council's Working Parties for Therapeutic Trials in Adult Leukaemia
26. Efficacy of STI571, an abl tyrosine kinase inhibitor, in conjunction with other antileukemic agents against bcr-abl-positive cells
27. Treatment of chronic hepatitis B: New antiviral therapies
28. Treatment strategies for chronic hepatitis C: Update since the 1997 National Institutes of Health Consensus Development Conference
29. Chronic hepatitis C and interferon alpha: Conventional and cumulative meta-analyses of randomized controlled trials
30. Chemo-immunotherapy of advanced AIDS-related Kaposi's sarcoma
31. Prospective randomized trial of two dose levels of interferon alfa with zidovudine for the treatment of Kaposi's sarcoma associated with human immunodeficiency virus infection: A Canadian HIV Clinical Trials Network study
32. Long-term treatment of myeloproliferative disease with interferon-α 2B
33. Interferon alpha in the treatment of polycythemia vera
34. Combined subcutaneous recombinant alpha-interferon and interleukin-2 in metastatic renal cell cancer: Results of the Multicentre All Ireland Immunotherapy Study Group
35. Phase III trial of interferon alfa-2A with or without 13-cis-retinoic acid for patients with advanced renal cell carcinoma
36. Infusional interleukin-2 and 5-fluorouracil with subcutaneous interferon-alpha for the treatment of patients with advanced renal cell carcinoma: A southwest oncology group phase II study
37. Cytokines in combination with chemotherapy for advanced renal carcinoma - The importance of patient selection
38. Interferon alpha-2A and 13-cis-retinoic acid in patients with metastatic renal cell cancer
39. Phase II trial of branch pegylated (40 kDa) interferon α-2a for patients with advanced renal cell carcinoma
40. Capecitabine in the treatment of metastatic renal cell carcinoma
41. Vinorelbine and interferon-alpha2c as second-line therapy in metastatic renal cell carcinoma
42. Recombinant interferon-alpha 2B and megestrol acetate in patients with advanced renal cell carcinoma
43. Phase I trial of combined immunotherapy with subcutaneous granulocyte macrophage colony-stimulating factor, low-dose interleukin 2, and interferon alpha in progressive metastatic melanoma and renal cell carcinoma
44. Cytokines and tumor vaccination
45. A randomized phase 11 trial comparing two different sequence combinations of autologous vaccine and human recombinant interferon gamma and human recombinant interferon alpha 2B therapy in patients with metastatic renal cell carcinoma: Clinical outcome and analysis of immunological parameters
46. Interpheron alpha primed tumor infiltrating lymphocytes combined with interleukin-2
47. Generation of monocyte-derived dendritic cells from patients with renal cell cancer: Modulation of their functional properties after therapy with biological response modifiers (IFN-alpha plus IL-2 and IL-12)
48. Prospective randomized trial of interferon alfa-2a plus vinblastine versus vinblastine alone in patients with advanced renal cell cancer
49. Clinical toxicity in cancer patients
50. Safety profile of interferon-α therapy
51. Cytokines and anorexia: A brief over-view
52. Fatigue: Definitions, mechanisms and paradigms for study
53. Endocrine-mediated mechanisms of fatigue during treatment with interferon-α
54. Cytokines and brain function: Relevance to interferon-α-induced mood and cognitive changes
55. Antibodies to interferon-α in treated cancer patients: Incidence and significance
56. Subcutaneous administration of IFN-alpha and gamma in patients with metastatic renal cell carcinoma
57. The role of adjuvant immunotherapy after radical nephrectomy and prognostic factors in pT 3N0M0 renal cell carcinoma
58. Immunochemotherapy with interleukin-2, interferon-alpha and 5-fluorouracil for progressive metastatic renal cell carcinoma: A multicenter phase II study. Dutch Immunotherapy Working Party
59. A phase II trial of interleukin-2 and interferon alfa- 2A in patients with advanced renal cell carcinoma
60. Randomized phase II trial of high-dose interleukin-2 either alone or in combination with interferon alfa- 2B in advanced renal cell carcinoma
61. Interferon alfa-2A in advanced renal cell carcinoma: Treatment results and survival in 159 patients with long-term follow-up
62. Intraperitoneal chemotherapy with carboplatin and interferon alpha in the treatment of relapsed ovarian cancer: A pilot study
63. Alpha interferon: The potential drug of adjuvant therapy. Past achievements and future challenges
64. Adjuvant therapy of stage IIIb melanoma with interferon alfa-2B
65. Adjuvant interferon treatment for melanoma
66. Interferon-alpha and -beta: Clinical applications: Melanoma
67. Potential applications of the interferons in oncology: Lessons drawn from studies of human melanoma
68. Activity of interferon-alpha in relapsed patients with diffuse large B-cell and peripheral T-cell non-Hodgkin's lymphoma
69. The role of recombinant interferon alfa-2A in the therapy of cutaneous T-cell lymphomas
70. Meta-analysis to assess the efficacy of interferon-alpha in patients with follicular non-Hodgkin's lymphoma
71. Meta-analysis in clinical trials
72. A randomized study of low and high doses of leukocyte α-interferon in metastatic renal cell carcinoma: The American Cancer Society Collaborative Trial
73. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: The Eastern Cooperative Oncology Group Trial EST 1684
74. High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: Results of inter-group trial E1694/S95I2/C50980I